Back to Search
Start Over
Hepatitis risk in cardiac surgery patients receiving factor IX concentrates
- Source :
- Journal of Thoracic and Cardiovascular Surgery; August 1979, Vol. 78 Issue: 2 p203-207, 5p
- Publication Year :
- 1979
-
Abstract
- Experience with the clinical use and hepatitis risks of factor IX concentrate (Proplex) in cardiac surgical patients is presented in this report. Seventy-five patients received the concentrate for severe intraoperative or postoperative hemorrhage and 75 patients constituted matched controls. The incidence of probable type B viral hepatitis in patients receiving factor IX concentrate was 13.8 percent (four of 29) versus zero percent (zero of 29) in control patients (difference not significant). However, there was a greater incidence (p < 0.05) of anti-HBsin patients receiving factor IX concentrate as compared to control subjects. No hepatitis-associated deaths or major morbidity were noted in these patients. It is confirmed that factor IX concentrate carries an associated significant risk of hepatitis. However, its use is justified in certain severe, acquired coagulopathies in which conventional platelet and fresh-frozen plasma therapy is inadequate.
Details
- Language :
- English
- ISSN :
- 00225223 and 1097685X
- Volume :
- 78
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic and Cardiovascular Surgery
- Publication Type :
- Periodical
- Accession number :
- ejs51733757
- Full Text :
- https://doi.org/10.1016/S0022-5223(19)38127-9